Entero Therapeutics (NASDAQ:ENTO) Stock Price Up 8.5% – What’s Next?

Entero Therapeutics, Inc. (NASDAQ:ENTO) shares were up 8.5% during trading on Wednesday . The company traded as high as $2.40 and last traded at $2.31. Approximately 140,680 shares changed hands during trading, an increase of 11% from the average daily volume of 126,532 shares. The stock had previously closed at $2.13.

Entero Therapeutics Price Performance

The stock has a 50 day simple moving average of $3.29 and a two-hundred day simple moving average of $3.43. The company has a market cap of $3.67 million, a PE ratio of -1.37 and a beta of 1.19.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics as of its most recent SEC filing. 12.30% of the stock is currently owned by institutional investors and hedge funds.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.